The United States dominates the global export of insulin not in dosage forms, with a substantial share of 87.33%. However, it experienced a slight decline of 3.02% in 2023. The Czech Republic and the United Kingdom showed growth, increasing by 2.32% and 3.08%, respectively, while Denmark, France, Italy, and Switzerland saw declines. Notably, Australia experienced significant growth of 17.08%, albeit from a smaller base. The compounded annual growth rates over the past five years reveal dynamic market conditions with varied performance across countries.
Looking forward, stakeholders should monitor regulatory developments, innovation in insulin production, and shifts in trade policies. These factors could significantly influence the future landscape of global insulin exports.
Top countries in Export of Insulin Not in Dosage Forms Share by Country (US Dollars)
| # | 10 Countries | Percent | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 87.33 | 2023 | -0.17% | -3.02% | View data |
| 2 | 2 Czech Republic | 1.92 | 2023 | +5.41% | +2.32% | View data |
| 3 | 3 Denmark | 1.3 | 2023 | -5.34% | -7.08% | View data |
| 4 | 4 United Kingdom | 0.55 | 2023 | +1.22% | +3.08% | View data |
| 5 | 5 France | 0.44 | 2023 | -4.47% | -4.13% | View data |
| 6 | 6 Austria | 0.34 | 2023 | +3.71% | +3.62% | View data |
| 7 | 7 Italy | 0.067 | 2023 | -10.63% | -13.1% | View data |
| 8 | 8 South Africa | 0.043 | 2023 | -10.85% | -8.05% | View data |
| 9 | 9 Australia | 0.024 | 2023 | -1.22% | +17.08% | View data |
| 10 | 10 Switzerland | 0.023 | 2023 | -9.82% | -18.91% | View data |
